Soricimed Biopharma Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$3M
Investors
45
Min Invest
$7,859
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Soricimed Biopharma Inc. is a New Brunswick, Canada corporation that first filed a Form D on January 31, 2022 and most recently amended it on January 19, 2023 in the Biotechnology industry group. The offering claims Rule 506(c) and covers equity. Soricimed Biopharma Inc. reported $2,775,233 sold from 45 investors of a $3,732,179 total offering as of the Form D filed January 19, 2023. The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $7,859. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 18 Botsford Street, Suite 201, Moncton, New Brunswick, Canada E1C 4W7.
Critical Disclosures
What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.
Reporting lapsed · Form D · last filing January 19, 2023
Offering declared to continue beyond a year; annual amendment 13+ months overdue An issuer that stops filing is the case the going-concern flag cannot catch: the report that would have carried it was never filed.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
dark
Investor
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2023-01-19: 0 related persons added and 1 removed against the filing of 2022-01-31; 7 now listed. The names are in the Terminal feed.
Robert Bruce
Executive Officer · MONCTON, A3
Chief Executive Officer
Jack Stewart
Executive Officer, Director · MONCTON, A3
Chief Science Officer and Director
Paul Gunn
Executive Officer, Director · MONCTON, A3
President and Director
Vaughn Embro-Pantelony
Director · MONCTON, A3
Chair
Marc Rubin
Director · MONCTON, A3
Camille Belliveau
Director · MONCTON, A3
Susan Hicks
Director · MONCTON, A3
Questions About Soricimed Biopharma Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Soricimed Biopharma Inc.?
Soricimed Biopharma Inc. is a New Brunswick, Canada corporation that filed a Form D with the SEC on January 19, 2023 in the Biotechnology industry group. The filing claims Rule 506(c) for an offering of equity.
Is Soricimed Biopharma Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Soricimed Biopharma Inc. filed a Form D with the SEC on January 19, 2023 claiming Rule 506(c). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $2,775,233 sold to 45 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Soricimed Biopharma Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Soricimed Biopharma Inc. claimed Rule 506(c) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Soricimed Biopharma Inc. raised?
Soricimed Biopharma Inc. reported $2,775,233 sold from 45 investors of a $3,732,179 total offering as of the Form D filed January 19, 2023.
Who can invest in Soricimed Biopharma Inc.?
The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $7,859.
What is the minimum investment in Soricimed Biopharma Inc.?
The Form D lists $7,859 as the minimum investment accepted from any outside investor as of January 19, 2023. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Soricimed Biopharma Inc. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Who is behind Soricimed Biopharma Inc.?
The Form D lists 7 related persons: Robert Bruce, executive officer (Chief Executive Officer); Jack Stewart, executive officer, director (Chief Science Officer and Director); Paul Gunn, executive officer, director (President and Director); Vaughn Embro-Pantelony, director (Chair); Marc Rubin, director; Camille Belliveau, director; Susan Hicks, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Soricimed Biopharma Inc. located?
The issuer's address on its SEC filings is 18 Botsford Street, Suite 201, Moncton, New Brunswick, Canada E1C 4W7. Its phone number of record is 1(506)872-2181. It is organized under the laws of New Brunswick, Canada.
How long is the Soricimed Biopharma Inc. offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.
What is Soricimed Biopharma Inc.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.